News articles about Matinas BioPharma Holdings (NASDAQ:MTNB) have trended somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Matinas BioPharma Holdings earned a news impact score of 0.21 on Accern’s scale. Accern also gave news stories about the company an impact score of 47.1216913028166 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Matinas BioPharma Holdings (MTNB) traded up 3.13% on Friday, reaching $1.32. 19,441 shares of the company’s stock were exchanged. The firm has a 50-day moving average of $1.30 and a 200-day moving average of $2.43. Matinas BioPharma Holdings has a 12 month low of $0.78 and a 12 month high of $3.99. The firm’s market capitalization is $121.40 million.

Matinas BioPharma Holdings (NASDAQ:MTNB) last announced its earnings results on Tuesday, August 8th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. The business had revenue of $0.05 million during the quarter, compared to analysts’ expectations of $0.02 million. Matinas BioPharma Holdings had a negative net margin of 30,034.20% and a negative return on equity of 1,227.85%. On average, equities analysts expect that Matinas BioPharma Holdings will post ($0.29) earnings per share for the current year.

Several research firms have recently commented on MTNB. Roth Capital set a $9.00 price target on shares of Matinas BioPharma Holdings and gave the company a “buy” rating in a report on Thursday, August 10th. Maxim Group set a $6.00 target price on shares of Matinas BioPharma Holdings and gave the company a “buy” rating in a research note on Tuesday, August 8th.

TRADEMARK VIOLATION NOTICE: This news story was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was stolen and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/09/01/matinas-biopharma-holdings-mtnb-given-news-impact-rating-of-0-21.html.

About Matinas BioPharma Holdings

Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections.

Receive News & Stock Ratings for Matinas BioPharma Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma Holdings Inc and related stocks with our FREE daily email newsletter.